1[10]NAKASHIMA M, UMEMURA K. The clinical pharmacology of losartan in Japanese subjects and patients[J]. Blood Press Suppl,1996,2:62-66.
2[11]SONG JC, WHITE CM. Pharmacologic, pharmacokinetic, and therapeutics differences among angiotensin Ⅱreceptor antagonists [J]. Pharmacotherapy, 2000,20(2):130-139.
3[12]NEUTEL JM, KLEIN C, MEINICKE TW, et al. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications[J].Blood Press,2002,11(5):302-309.
4[13]PRASAD PP, YEH CM, GURRIERI P, et al. Pharmacokinetics of multiple doses of valsartan in patients with heart failure[J]. J Cardiovasc Pharmacol,2002,40(5):801-807.
5[14]SMITH DH, MATZEK KM, KEMPTHORNE-RAWSOWL J. Dose response and safety of telmisartan in patients with mild to moderate hypertension[J]. J Clin Pharmacol,2000,40(12 Pt 1):1380-1390.
6[15]SASAKI M, FUJIMURA A, HARADA K, et al. Clinical pharmacology of multiple-dose losartan an angiotensin Ⅱ receptor antagonist, in patients with essential hypertension[J]. J Clin Pharmacol, 1996, 36(5):403-408.
7[16]RUILOPE L. Human pharmacokinetic/pharmacodynemic profile of irbesartan: a new potent angiotensin Ⅱ receptor antagonist[J]. J Hypertens Suppl,1997 ,15 (7):S15-S20.
8[17]McCLELLAN KJ, GOA KL. Candesartan cilexetil. A review of its use in essential hypertension[J]. Drugs,1998,56(5):847-869.
9[18]PHILIPP T, LETZEL H, ARENS HJ. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension[J]. J Hum Hypertens,1997 ,11 Suppl 2:S67-S68.
10[19]McGILL JB, REILLY PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized ,double-blind, placebo-controlled, parallel-group trial [J]. Clin Ther,2001, 23(6):833-850.
